US filing imminent for potential blockbuster antibody-drug conjugate
The UK’s AstraZeneca (LSE: AZN) has unveiled positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of the breast cancer candidate trastuzumab deruxtecan, known as DS-8201.
In March, AstraZeneca inked a major deal with the Japanese firm Daiichi Sankyo (TYO: 4568), agreeing to pay as much as $6.9 billion to buy into the promising treatment.
Under the terms of the deal, Daiichi Sankyo received an upfront payment of $1.35 billion, plus milestone commitments, in return for joint global development and commercialization, apart from in Japan, where Daiichi will maintain exclusive rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze